About the Author
Werner Barnard MBChB (Pret), LMCC, MCFP
Dr. Barnard is a family physician with a special interest in allergy. He obtained his medical degree MB.ChB from the University of Pretoria, South Africa in 1989 and moved to Canada in 1998 where he worked in a rural community as a family physician until 2004. Subsequently, he established a focused practice in allergy in Regina in 2005. He is a member of the European Academy of Allergy and Clinical Immunology. Dr. Barnard is also an Assistant Clinical Professor at the University of Saskatchewan and has served as a consultant on various advisory Boards.
Antihistamines in CSU: Practice Points
Urticaria is a mast cell mediated condition characterized by transient, raised, pruritic wheals on an erythematous background, with each individual lesion resolving within 24-48 hours without bruising or scarring. Angioedema (AE) is localized subcutaneous swelling which may occur with urticaria, or independently. Urticaria is classified as acute or chronic depending on the duration. Chronic urticaria is further subdivided into inducible or chronic spontaneous. The focus of this article will be chronic spontaneous urticaria (CSU), which is characterized by wheals and/or swelling occurring spontaneously on most days of the week for 6 weeks or more (Figure 1). The prevalence of chronic urticaria has been estimated to be 0.5–5%. Chronic urticaria is more common in adults, with a peak age of onset between 20 and 40 years, affecting women more frequently than men. In CSU, an external trigger cannot usually be identified.1
Current global urticaria consensus guidelines recommend that first line treatment for CSU consists of regular daily use of a second-generation long-acting non-sedating antihistamine at standard dose. If no response or inadequate response is observed in 2-4 weeks or sooner, second line treatment is advised with two, three or four times the standard dose, usually divided in two daily doses. (Figure 2) Spontaneous remission of CSU occurs in up to 50% of patients within 6 months or less, but the average duration is 3-5 years.
While disease-modifying drugs are currently not available for CSU, the objective of treatment is to control or suppress symptoms impacting on the patient’s quality of life until remission occurs. Due to the chronic nature of the disease and the requirement for continuous treatment for months or years, it is important that therapies used are well-tolerated and without significant long-term morbidity.
Second generation (non-sedating) H1 antihistamines
Second generation antihistamines available in Canada include cetirizine, loratadine, desloratadine, fexofenadine, bilastine and rupatadine. Although comparative studies suggest that all second-generation antihistamines may not be equally effective in CSU, there is not sufficient evidence to make strong recommendations for or against any of these antihistamines at the current time.
All the therapies mentioned have proven efficacy in CSU as evidenced by their key registration trials, which include a total of nearly 4,000 patients and all have demonstrated safety and efficacy with no significant adverse effects. Reported levels of somnolence and sedation are consistently comparable with placebo-treated patients and significant improvements in health-related quality of life, work performance and activities of daily living have also been reported. Minor adverse events have been noted in a minority of patients, including headache, drowsiness, constipation, and abdominal pain.2-25
Second-generation H1 antihistamines are generally well tolerated by most patients, even at high doses. A recent retrospective analysis examined data from one centre in which antihistamines were up-dosed at doses greater than four times the standard dose. The objective of this study was to investigate the frequency of ineffectiveness of treatment with antihistamines up to fourfold the standard dose in patients with CSU, and to determine the effectiveness and safety of antihistamine treatment above fourfold the standard dose.The investigators reported that of 200 screened patients, 178 were included in the final analysis and that treatment started with a once-daily dose of antihistamines. Persisting symptoms meant that up-dosing up to fourfold occurred in 138 (78%) of patients, yielding sufficient response in 41 (23%). Up-dosing antihistamines was necessary in 110 (80%) patients with weals alone or weals with AE and 28 (64%) with AE only (p = 0.039) and side effects after up-dosing higher than fourfold were reported in 10% of patients (6/59).26 However, given this is a single study, a recommendation to increase to greater than 4 times the current dose cannot be made at this time.
Treatment of CSU in pediatric populations
Evidence to date suggest that the prevalence and causes of CSU in the pediatric population are similar to that in adults35,36 and second-generation long-acting antihistamines remain the mainstay of treatment. First-generation antihistamines should be avoided due to the higher incidence of adverse events
Treatment of CSU in pregnancy and lactation
During pregnancy therapeutic agents used to achieve control of symptoms, particularly pruritus should be used sparingly. The majority of patients can be treated during pregnancy and lactation with second-generation H1 antihistamines. There is no data available on the advisability of escalating the currently recommended doses of antihistamines in pregnancy, and careful discussion regarding benefits and risks of available treatment options is advised.
1. Zuberbier, Torsten, et al. “The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.” Allergy 73.7 (2018): 1393-1414.
2. Augustin, M., and S. Ehrle. “Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients.” Journal of the European Academy of Dermatology and Venereology 23.3 (2009): 292-299.
3. Breneman, Debra L. “Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria.” Annals of Pharmacotherapy 30.10 (1996): 1075-1079.
4. Finn Jr, Albert F., et al. “A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.” Journal of allergy and clinical immunology 104.5 (1999): 1071-1078.
5. Goh, C. L., W. K. Wong, and J. Lim. “Cetirizine vs placebo in chronic idiopathic urticaria–a double blind randomised cross-over study.” Annals of the Academy of Medicine, Singapore 20.3 (1991): 328-330.
6. Grob, J. J., et al. “Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study.” Journal of the European Academy of Dermatology and Venereology 22.1 (2008): 87-93.
7. Grob, J-J., et al. “How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life.” Allergy 64.4 (2009): 605-612.
8. Juhlin, L., and C. Arendt. “Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine.” British Journal of Dermatology 119.1 (1988): 67-72.
9. Juhlin, L. “Cetirizine in the treatment of chronic urticaria.” Clinical therapeutics 13.1 (1991): 81-86.
10. Kalivas, James, et al. “Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo.” Journal of allergy and clinical immunology 86.6 (1990): 1014-1018.
11. Kaplan, Allen P., et al. “Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study.” Annals of Allergy, Asthma & Immunology 94.6 (2005): 662-669.
12. Kapp, Alexander, and Werner J. Pichler. “Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, parallel, multicenter study.” International journal of dermatology 45.4 (2006): 469-474.
13. Kawashima, Makoto, and Shotaro Harada. “Efficacy and safety of fexofenadine HCl in Japanese patients with chronic idiopathic urticaria.” International archives of allergy and immunology 124.1-3 (2001): 343.
14. Koti, I1, et al. “Disease activity only moderately correlates with quality of life impairment in patients with chronic spontaneous urticaria.” Dermatology 226.4 (2013): 371-379.
15. Kulthanan, Kanokvalai, et al. “Multicenter study of the efficacy and safety of fexofenadine 60 mg. twice daily in 108 Thai patients with chronic idiopathic urticaria.” Journal of the Medical Association of Thailand= Chotmaihet thangphaet 84.2 (2001): 153-159.
16. Monroe, E. W., et al. “Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria.” Arzneimittel-forschung 42.9 (1992): 1119-1121.
17. Monroe, E. W. “Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis.” Clinical therapeutics 14.1 (1992): 17-21.